Moxifloxacin: new indication. Inadequate restriction of indications in ENT and respiratory infections.Prescrire Int. 2009 Oct; 18(103):206.PI
Abstract
Moxifloxacin carries an increased risk of fatal adverse effects and yet is no more effective than other fluoroquinolones. It should simply be taken off the market.
MeSH
Pub Type(s)
Journal Article
Language
eng
PubMed ID
19882787
Citation
"Moxifloxacin: New Indication. Inadequate Restriction of Indications in ENT and Respiratory Infections." Prescrire International, vol. 18, no. 103, 2009, p. 206.
Moxifloxacin: new indication. Inadequate restriction of indications in ENT and respiratory infections. Prescrire Int. 2009;18(103):206.
(2009). Moxifloxacin: new indication. Inadequate restriction of indications in ENT and respiratory infections. Prescrire International, 18(103), 206.
Moxifloxacin: New Indication. Inadequate Restriction of Indications in ENT and Respiratory Infections. Prescrire Int. 2009;18(103):206. PubMed PMID: 19882787.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR
T1 - Moxifloxacin: new indication. Inadequate restriction of indications in ENT and respiratory infections.
PY - 2009/11/4/entrez
PY - 2009/11/4/pubmed
PY - 2009/12/16/medline
SP - 206
EP - 206
JF - Prescrire international
JO - Prescrire Int
VL - 18
IS - 103
N2 - Moxifloxacin carries an increased risk of fatal adverse effects and yet is no more effective than other fluoroquinolones. It should simply be taken off the market.
SN - 1167-7422
UR - https://www.unboundmedicine.com/medline/citation/19882787/Moxifloxacin:_new_indication__Inadequate_restriction_of_indications_in_ENT_and_respiratory_infections_
DB - PRIME
DP - Unbound Medicine
ER -